BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 12220138)

  • 1. Beyond HIV, HBV and HCV--how to deal with other viruses?
    Minor PD
    Dev Biol (Basel); 2002; 108():15-9. PubMed ID: 12220138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Status of NAT screening for HCV, HIV and HBV--experiences of the German Red Cross Blood Donation Services.
    Seifried E; Findhammer S; Roth WK
    Dev Biol (Basel); 2002; 108():23-7. PubMed ID: 12220139
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
    Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
    Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-borne viral infections.
    Gürtler L
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S5-10; discussion S11-2. PubMed ID: 7749048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Status of NAT screening for HCV, HIV and HBV: experience in Japan.
    Tomono T; Murokawa H; Minegishi K; Yamanaka R; Lizuka HY; Miyamoto M; Satoh S; Nakahira S; Murozuka T; Emura H; Doi Y; Mine H; Yokoyama S; Ohnuma H; Tanaka T; Yoshikawa A; Nishioka K;
    Dev Biol (Basel); 2002; 108():29-39. PubMed ID: 12220140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited effectiveness of donor deferral registries for transfusion-transmitted disease markers.
    Cable R; Musavi F; Notari E; Zou S;
    Transfusion; 2008 Jan; 48(1):34-42. PubMed ID: 17894796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfusional transmitted viruses in pregnancy.
    Eleftheriou A; Kalakoutis G; Pavlides N
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():901-14. PubMed ID: 10091164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific inactivation of viruses which can potentially contaminate blood products.
    Horowitz B
    Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.
    Shang G; Seed CR; Wang F; Nie D; Farrugia A
    Transfusion; 2007 Mar; 47(3):529-39. PubMed ID: 17319836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA.
    McCormick MK; Dockter J; Linnen JM; Kolk D; Wu Y; Giachetti C
    J Clin Virol; 2006 Jul; 36(3):166-76. PubMed ID: 16427802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion-transmitted infection in hemophilia in developing countries.
    Yee TT; Lee CA
    Semin Thromb Hemost; 2005 Nov; 31(5):527-37. PubMed ID: 16276461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion-transmitted infectious diseases.
    Allain JP; Stramer SL; Carneiro-Proietti AB; Martins ML; Lopes da Silva SN; Ribeiro M; Proietti FA; Reesink HW
    Biologicals; 2009 Apr; 37(2):71-7. PubMed ID: 19231236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
    Corash L
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in transfusion-transmitted viral infections from 2001 to 2006 in Ibadan, Nigeria.
    Fasola FA; Kotila TR; Akinyemi JO
    Intervirology; 2008; 51(6):427-31. PubMed ID: 19321928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection.
    Nübling CM; Chudy M; Volkers P; Löwer J
    Transfusion; 2006 Nov; 46(11):1886-91. PubMed ID: 17076842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
    Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
    Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
    Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Possibilities of virus inactivation of pooled fresh plasma with tri-n-butylphosphate (TNBP) detergents (SD procedure)].
    Gürtler L
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():77-9. PubMed ID: 8000260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.
    Seed CR; Kiely P; Keller AJ
    Intern Med J; 2005 Oct; 35(10):592-8. PubMed ID: 16207258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance of the genetic variation in incident HIV, HCV, and HBV infections in blood and plasma donors: implications for blood safety, diagnostics, treatment, and molecular epidemiology.
    Delwart E; Kuhns MC; Busch MP
    J Med Virol; 2006; 78 Suppl 1():S30-5. PubMed ID: 16622875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.